Coexistence of fluoroquinolone resistance and ESBL production in urinary isolates

Nazia Khan, Pragyan Swagatika Panda, Megha Rastogi, Swati Sharma, Neha Rana, Maryam Faridi, Man Mohan Mehndiratta


Background: Enterobacteriaceae group of organisms are commonly implicated for causing urinary tract infection (UTI). Fluoroquinolones (FQ) are widely used as empirical therapy for UTI. Enterobacteriaceae exhibits high resistance rates to FQs. The plasmid mediated extended spectrum beta lactamase (ESBL) production confers resistance for FQs as well. The aim of the study is to determine the prevalence of fluoroquinolones resistance in urinary isolates and to study the coexistence of FQ resistance and ESBL production in urinary isolates.

Methods: Retrospective data of the urine samples received in our microbiology laboratory between December 2018 to May 2019 were reviewed. The organisms were isolated and identified as per standard procedures and the antibiotic susceptibility testing was done following CLSI 2019 guidelines. Ceftazidime (30 µg) and ceftazidime-clavulinic acid (30 µg/10 µg) were used for detection of ESBL production.  Levofloxacin (5 µg) and ciprofloxacin (5 µg) were used for detecting FQ resistance.

Results: Out of a total of 1403 urine samples received in our laboratory, 240 (17.1%) sample showed growth of Enterobacteriaceae. The different species were E. coli (80.4%), Klebsiella spp (12.2%), Citrobacter spp (4.2%), Enterobacter spp (1.6%) and Proteus mirabilis (1.6%). Amongst these organisms 121(50.4%) were ESBL producers. Co-existence of FQ resistance among the ESBL producers was observed in 106(87.6%) isolates which is higher as compared to that among the ESBL non producers 71(59.7%).

Conclusions: Around 50% of the UTI Enterobacteriaceae bacteria are ESBL producers. Fluroquinolone resistance amongst ESBL producing Enterobacteriaceae is very high (87.6%).


ESBL, Fluroquinolone, Infection, Resistance, Urinary tract infection

Full Text:



Stamm WE, Norrby SR. Urinary tract infections: disease panorama and challenges. The J Infect Dis 2001;183(1):1-4.

Tan CW, Chlebicki MP. Urinary tract infections in adults. Singapore Med J 2016;57(9):485-90.

Aldred KJ, Kerns RJ, Osheroff N. Mechanism of quinolone action and resistance. Biochem 2014;53(10):1565-74.

Paterson DL. Recommendation for treatment of severe infections caused by Enterobacteriaceae producing extended-spectrum β-lactamases (ESBLs). Clin Microbiol Infect 2000;6(9):460-3.

Mammeri H, Van De Loo M, Poirel L, Martinez-Martinez L, Nordmann P. Emergence of plasmid-mediated quinolone resistance in Escherichia coli in Europe. Antimicrob Agents Chemother. 2005;49(1):71-6.

Wang M, Sahm DF, Jacoby GA, Hooper DC. Emerging plasmid-mediated quinolone resistance associated with the qnr gene in Klebsiella pneumoniae clinical isolates in the United States. Antimicrob Agents Chemother. 2004;48(4):1295-9.

Clinical and Laboratory Standard Institute. Performance standard for antimicrobial susceptibility testing. twenty ninth Informational Supplement. CLSI document M100–S29. Wanye PA, USA; CLSI; 2019:104-6.

Kim SY, Park Y, Kim H, Kim J, Koo SH, Kwon GC. Rapid screening of urinary tract infection and discrimination of Gram-positive and Gram-negative bacteria by automated flow cytometric analysis using Sysmex UF-5000. J Clin Microbiol. 2018;56(8):e02004-17.

Kao CY, Wu HM, Lin WH, Tseng CC, Yan JJ, Wang MC et al. Plasmid-mediated quinolone resistance determinants in quinolone-resistant Escherichia coli isolated from patients with bacteremia in a university hospital in Taiwan, 2001–2015. Sci Rep. 2016;6:32281.

Bouchillon S, Hoban DJ, Badal R, Hawser S. Fluoroquinolone resistance among gram-negative urinary tract pathogens: global smart program results, 2009-2010. Open Microbiol J. 2012;6:74-8.

Arundathi HA, Koppad M, Halesh LH, Siddesh KC. Coexistence of quinolone resistance and extended spectrum beta lactamase production in urinary isolates of Escherichia coli-an emerging challenge to antimicrobial prescribing pattern. Indian J Microbiol Res. 2016;3(4):359-62.

Shahcheraghi F, Moezi H, Feizabadi MM. Distribution of TEM and SHV beta-lactamase genes among Klebsiella pneumoniae strains isolated from patients in Tehran. Med Sci Monit. 2007;13(11):247-50.

Neuhauser MM, Weinstein RA, Rydman R, Danziger LH, Karam G, Quinn JP. Antibiotic resistance among gram-negative bacilli in US intensive care units: implications for fluoroquinolone use. JAMA. 2003;289(7):885-8.

Tumbarello M, Spanu T, Sanguinetti M, Citton R, Montuori E, Leone F et al. Bloodstream infections caused by extended-spectrum-β-lactamase-producing Klebsiella pneumoniae: risk factors, molecular epidemiology, and clinical outcome. Antimicrob Agents Chemother. 2006;50(2):498-504.

Magesh H, Kamatchi C, Vaidyanathan R, Sumathi G. Identification of plasmid-mediated quinolone resistance genes qnrA1, qnrB1 and aac (6')-1b-cr in a multiple drug-resistant isolate of Klebsiella pneumoniae from Chennai. Indian J Med Microbiol. 2011;29(3):262-8.